Advertisement
ARCT vs VCYT
Which Stock Would AI Choose? Arcturus Therapeutics Holdings (ARCT) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Different stages of maturity: ARCT is a clinical-stage messenger RNA (mRNA) medicines company, while VCYT is a profitable, commercially established genomic diagnostics company.
- Contrasting fundamentals: VCYT generates positive earnings and free cash flow with no debt, whereas ARCT remains loss-making and depends on collaborations for revenue.
- Momentum diverges: ARCT has shown sharp, high-beta swings on clinical news, while VCYT has trended upward over the past year but pulled back recently.
- Analyst sentiment: Both names carry constructive consensus ratings, with ARCT holding a "Strong Buy" consensus and VCYT supported by positive estimate revisions.
- Risk profiles differ sharply: ARCT carries binary clinical and regulatory risk, while VCYT faces reimbursement and competitive pressures in diagnostics.
Introduction
This stock comparison examines two healthcare companies operating at opposite ends of the risk spectrum. Arcturus Therapeutics Holdings (NASDAQ: ARCT) is a clinical-stage developer of mRNA-based therapeutics and vaccines, while Veracyte (NASDAQ: VCYT) is a profitable provider of genomic diagnostic tests used in cancer care. Their relative performance and market positioning offer a useful lens for investors weighing speculative, catalyst-driven biotech exposure against a steadier, revenue-generating diagnostics franchise. Understanding how these companies differ in business model, growth drivers, and risk can help traders and long-term investors evaluate which profile better matches their objectives in the current market environment.
ARCT Overview and Recent Performance
Arcturus Therapeutics Holdings is a San Diego-based clinical-stage mRNA medicines company focused on rare diseases and infectious-disease vaccines. Its technology platform centers on the LUNAR lipid-mediated delivery system and the STARR self-amplifying mRNA approach. Recent weeks have featured notable pipeline momentum: interim Phase 2 data for ARCT-810, its investigational therapy for ornithine transcarbamylase (OTC) deficiency, were reported as generally safe and well-tolerated, and the company unveiled a next-generation delivery platform known as LUNAR 2.0.
This news has coincided with meaningful share-price volatility. The stock rallied sharply at times on clinical updates and a strategic collaboration with Thermo Fisher Scientific supporting late-stage development of ARCT-032 for cystic fibrosis, while also announcing an agreement to acquire myNEO to strengthen its computational and artificial-intelligence capabilities. However, revenue has contracted as collaboration-related payments stepped down, and the company continues to post operating losses. With a beta above 2.0, ARCT remains a high-volatility, catalyst-sensitive name whose value rests heavily on future clinical and regulatory outcomes.
VCYT Overview and Recent Performance
Veracyte is a global diagnostics company that develops and commercializes genomic tests for cancer, anchored by its Afirma thyroid test and Decipher Prostate genomic classifier. The company has posted consistent double-digit testing-volume and revenue growth, with Decipher Prostate revenue rising roughly 20% and Afirma revenue increasing around 18% in recent quarters. Unlike its comparison peer, Veracyte is profitable, generating positive net income and maintaining a debt-free balance sheet with substantial cash reserves.
Recent market activity has nonetheless been mixed. Despite solid fundamentals, VCYT shares pulled back sharply over the past month, reflecting investor caution around reimbursement uncertainty and commercialization execution. The company recently launched Prosigna LDT for breast cancer in the U.S. and TrueMRD for muscle-invasive bladder cancer, but neither has yet contributed to guidance. Competitive pressure from rivals in molecular residual disease testing and guideline-driven softening in low-risk prostate cancer demand add further nuance to the growth story.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and basket of securities. Because market conditions shift continuously, only the bots best suited to the current environment earn a place in Tickeron's curated Trending AI Robots section. This selection highlights strategies with strong recent performance and favorable alignment to prevailing trends, helping traders filter a broad universe down to a focused watchlist. Whether you are evaluating names like ARCT and VCYT or scanning the wider market, exploring the Trending AI Robots page can offer data-driven context for your next move.
Head-to-Head Comparison
The core contrast between these two companies is business maturity. Veracyte operates a scaled, cash-generating diagnostics platform with recurring test volume, established reimbursement, and broad guideline inclusion for its flagship tests. Arcturus, by contrast, is a pre-commercial biotech whose revenue is dominated by milestone and collaboration payments that have proven lumpy and, recently, sharply lower.
Growth drivers also differ. VCYT's trajectory depends on commercial execution, test adoption, reimbursement decisions, and new product launches, which are generally incremental and measurable. ARCT's upside hinges on binary clinical data readouts, regulatory approvals, and future partnerships across its rare-disease and vaccine pipeline, producing a wider range of potential outcomes.
On risk, ARCT carries elevated clinical, financing, and execution risk alongside its high beta. VCYT carries more moderate but still meaningful risks around reimbursement, competition, and the pace of new-launch monetization. Sector exposure also differs: ARCT sits within high-risk biotechnology, while VCYT is classified among diagnostics and life-sciences tools.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, balance-sheet strength, and the nature of near-term catalysts, Tickeron's AI would likely favor VCYT in the current environment. Veracyte offers a steadier, more predictable fundamental profile, positive cash generation, and a debt-free balance sheet, qualities that tend to align with trend-following and lower-volatility strategies. ARCT, while supported by a "Strong Buy" consensus and meaningful potential upside, exhibits higher volatility and binary event risk that makes its relative positioning more dependent on individual clinical outcomes. This assessment reflects a probabilistic, data-driven view of relative positioning rather than a definitive prediction, and outcomes could shift as new catalysts unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and VCYT is a StrongBuy.
ARCT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where ARCT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.628) is normal, around the industry mean (3.043). P/E Ratio (-2.955) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VCYT in upward trend: 10-day moving average broke above 50-day moving average on October 02, 2026
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 87 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.775) is normal, around the industry mean (66.137). P/E Ratio (33.285) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
ARCT | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 98 | |
SMR RATING 1..100 | 98 | 75 | |
PRICE GROWTH RATING 1..100 | 39 | 44 | |
P/E GROWTH RATING 1..100 | 94 | 94 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for VCYT (70) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than VCYT’s over the last 12 months.
VCYT's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew similarly to ARCT’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew similarly to ARCT’s over the last 12 months.
ARCT's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as VCYT (44) in the Biotechnology industry. This means that ARCT’s stock grew similarly to VCYT’s over the last 12 months.
ARCT's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as VCYT (94) in the Biotechnology industry. This means that ARCT’s stock grew similarly to VCYT’s over the last 12 months.
| ARCT | VCYT | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| MACD ODDS (%) | N/A | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| Advances ODDS (%) | 4 days ago 82% | 4 days ago 73% |
| Declines ODDS (%) | 1 day ago 88% | 12 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 87% | 6 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- ARCT’s FA Score: 1 green, 4 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 3 TA indicator(s) are bullish while VCYT’s TA Score has 6 bullish TA indicator(s).
- ARCT’s TA Score: 3 bullish, 5 bearish.
- VCYT’s TA Score: 6 bullish, 4 bearish.
Price Growth
ARCT (@Biotechnology) experienced а -4.84% price change this week, while VCYT (@Medical Specialties) price change was +11.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
ARCT is expected to report earnings on Nov 09, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JHDG | 27.85 | 0.07 | +0.25% |
| John Hancock Hedged Equity ETF (JHDG) | |||
| DGJA | 32.31 | N/A | N/A |
| FT Vest U.S. Equity Buffer & Digital Return ETF - January (DGJA) | |||
| GDEC | 40.86 | -0.09 | -0.21% |
| FT Vest U.S. Equity Moderate Buffer ETF - December (GDEC) | |||
| PFFA | 18.78 | -0.15 | -0.79% |
| Virtus InfraCap U.S. Preferred Stock ETF (PFFA) | |||
| NOVZ | 47.33 | -0.43 | -0.90% |
| TrueShares Structured Outcome (November) ETF (NOVZ) | |||